X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ZN-c3 (azenosertib) is a potentially first-in-class and best-in-class small molecule WEE1 inhibitor in development for the treatment of ovarian cancer and uterine serous carcinoma.
Lead Product(s): ZN-C3,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Zentalis and Pfizer will initiate a Phase 1/2 dose escalation study of ZN-c3 in combination with encorafenib and cetuximab—an FDA-approved standard of care known as the BEACON regimen—in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC).
Lead Product(s): ZN-C3,Encorafenib,Cetuximab
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 24, 2022
Details:
Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 27, 2022
Details:
ZN-c3 showed robust clinical activity in an advanced, sicker patient population (57% had prior pembrolizumab/lenvatinib use), specifically demonstrating a deepening of tumor response, which included one patient who achieved an unconfirmed complete response.
Lead Product(s): ZN-C3,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all chemotherapy cohorts, also exhibit a better hematologic and gastrointestinal tolerability profile within Wee1 inhibitor class.
Lead Product(s): ZN-C3,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Through this partnership, Caris will sequence individuals’ complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis’ clinical trials.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Caris Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 29, 2022
Details:
SU2C-funded researchers can utilize Zentalis’ ZN-c3 to study the role of Wee1 in tumor growth in depth and use this information to potentially develop new therapeutic strategies utilizing Wee1 inhibition.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SU2C Catalyst
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 15, 2022
Details:
ZN-c3, a potent and selective WEE-1 inhibitor demonstrates durable clinical activity and good tolerability in varying indications anti-tumor activities in combination with other targeted therapies and overcomes PARP inhibitor resistance.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Zentera plans to use the proceeds to advance the clinical development in China of three of Zentalis’ product candidates, its WEE1 inhibitor ZN-c3, its oral SERD ZN-c5, and its BCL-2 inhibitor ZN-d5, as well as expand its pipeline.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 02, 2021
Details:
Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study with GSK providing all required doses of niraparib. Zentalis maintains full ownership of ZN-c3.
Lead Product(s): ZN-C3,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zentalis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 12, 2021
Details:
Zentalis Pharmaceuticals reported that three abstracts have been accepted for presentation, including a late-breaker on its WEE1 inhibitor, ZN-c3, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021.
Lead Product(s): ZN-C3
Therapeutic Area: Oncology Product Name: ZN-c3
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
